RIPK1 inhibitors are currently being investigated in several human clinical trials for neurodegenerative diseases, such as ALS and AD; and autoimmune diseases, such as psoriasis, rheumatoid arthritis, and ulcerative colitis (Clinical trials: NCT02776033, NCT02858492, NCT02903966, NCT03757351, and NCT03757325). The gene discussed is RIPK1; the disease is Alzheimer disease.